“2024-2029 French Pharma Market” report provides a presentation of the French healthcare system and of the latest measures introduced by health authorities. The report also reviews the current positions of the various stakeholders, evaluates their likely evolutions by 2029 and estimates the impact of these evolutions on the pharma market and on pharma companies strategic priorities
DESCRIPTION
- “2024-2029 French Pharma Market” report provides a description of the French healthcare system from a legal, organizational and economic point of view.
- This edition offers in a clear, precise and concise format:
- A documented, detailed and robust analysis of the French pharma market and of the latest measures introduced by health authorities, until March 2025
- An analysis of the current positions of stakeholders and of their likely evolutions by 2029
- An assessment of the impact of these evolutions on the pharmaceutical market and on companies by 2029
- Electronic copy: 434 pages (PowerPoint)
- Language: English